An "EZ" Epigenetic Road to Leukemia Stem Cell Metabolic Reprogramming?

Area of Science:

• Hematology
• Cancer Biology
• Epigenetics

Background:

• Myeloproliferative neoplasms (MPNs) are a group of blood cancers characterized by the overproduction of myeloid cells.
• The genetic drivers and underlying mechanisms of leukemic stem cell transformation in MPNs are not fully understood.
• Epigenetic dysregulation plays a crucial role in the development and progression of various cancers, including myeloid malignancies.

Purpose of the Study:

• To develop a novel mouse model for MPN driven by cooperating NRAS and EZH2 mutations.
• To investigate the role of these mutations in malignant transformation and metabolic reprogramming of leukemic stem cells.
• To identify potential therapeutic vulnerabilities in MPNs.

Main Methods:

• Development of a genetically engineered mouse model (GEMM) expressing NRASG12D and EZH2 mutations.
• Analysis of leukemic stem cell populations using flow cytometry and single-cell RNA sequencing.
• Metabolomic profiling to assess metabolic reprogramming in leukemic cells.
• In vivo and in vitro functional assays to evaluate therapeutic targeting.

Main Results:

• The NRASG12D and EZH2 mutations cooperate to induce aggressive myeloproliferative neoplasms in mice.
• Malignant transformation is associated with significant metabolic reprogramming of leukemic stem cells.
• Loss of normal epigenetic regulation by EZH2 contributes to leukemogenesis.
• The study identifies EZH1 and branched chain amino acid metabolism as critical dependencies.

Conclusions:

• The developed mouse model recapitulates key features of human MPNs.
• Cooperation between NRAS and EZH2 mutations drives leukemic stem cell dependency on EZH1 and specific metabolic pathways.
• Targeting EZH1 and branched chain amino acid metabolism represents a promising therapeutic strategy for myeloid neoplasms.